Lonza Group Ltd (0QNO.IL)
| Previous close | 402.20 |
| Open | 401.50 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 396.40 - 404.10 |
| 52-week range | 396.40 - 767.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin
Lonza Group AG / Key word(s): Annual Results25-Jan-2023 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Ad hoc announcement pursuant to Art. 53 LR In 2022, Lonza delivered CHF 6.2 billion sales and 15.1%1 CER sales growth CHF 2.0 billion CORE EBITDA resulted in a margin of 32.1% Growth investment continues as 2022 CAPEX reached 30% of sales Group Outlook 2023: high single-digit CER sales growth and CORE
- EQS Group
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
Lonza Group AG / Key word(s): Product LaunchLonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine 01.11.2022 / 07:00 CET/CEST Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sensitive APIs Innovative Capsugel® Enprotect™ capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelinesBasel, Switzerland, 1 November 2022 – Lonza,
- EQS Group
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
Lonza Group AG / Key word(s): PersonnelLonza Appoints Daniel Palmacci as President of the Cell & Gene Division 12.09.2022 / 07:00 CET/CEST Daniel Palmacci joins Lonza as President of the Cell & Gene Division and member of the Executive Committee Daniel will commence his tenure with Lonza Group on 1 November 2022, bringing deep industry knowledge, international experience and expertise in leading cross-functional teams Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, who w
